Le Lézard
Classified in: Health, Business
Subject: JVN

Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing

Celgene to receive exclusive options to license a number of Skyhawk's product candidates directed to multiple high-value autoimmune disorder, oncology, and immuno-oncology targets. 

Skyhawk to receive $80 Million upfront payment and is eligible for potential milestone payments and royalties.

WALTHAM, Mass., Nov. 12, 2019 /CNW/ -- Skyhawk Therapeutics, Inc. (Skyhawk) today announced that it has entered into a second global strategic collaboration with an affiliate of Celgene Corporation (NASDAQ: CELG).  This new agreement follows the June 2018 collaboration between the two companies and focuses on targets relevant to the field of autoimmune disorders, oncology, and immuno-oncology, providing further validation of Skyhawk's proprietary SkySTARTM technology platform.  The scope of the collaboration allows the parties to systematically interrogate a range of targets that have been clinically validated or are highly associated with the genetic basis of disease but have been considered undruggable using conventional small molecule therapies.

Skyhawk Therapeutics, Inc. (PRNewsfoto/Skyhawk Therapeutics)

Under the collaboration agreement, Skyhawk grants Celgene options to exclusively license worldwide intellectual property rights to candidates discovered and developed under the collaboration that are directed to program targets.  Following Celgene's exercise of its option, Celgene will be responsible for further development and commercialization.  

"Our impressive progress to date on targets that are part of our 2018 collaboration has led Celgene to enter into this new agreement focused on challenging targets beyond neurology," said Bill Haney, co-founder and CEO of Skyhawk Therapeutics. "This provides further evidence of the ability of our SkySTARTM technology platform to rapidly identify druggable sites and unique chemical matter to correct mRNA mis-splicing that may result in new treatment options for patients.  We look forward to the advancement of programs under this new collaboration and the potential to bring new treatment options to patients with unmet medical needs."

"The Skyhawk team's rapid and substantive progress demonstrates to us the unique advantages of the SkySTARTM platform and led us to expand our relationship.  We see Skyhawk's platform as a key disruptive technology that will support the autoimmune, oncology and immuno-oncology pipelines of the company we are today, and the company we are planning to be," said Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil., President, Research & Early Development, Celgene Corporation."

About Skyhawk Therapeutics
Skyhawk Therapeutics is committed to discovering, developing and commercializing therapies that use its novel SkySTARTM (Skyhawk Small molecule Therapeutics for Alternative splicing of RNA) platform to build small molecule drugs that bring breakthrough treatments to patients.

For more information visit:

Anne Deconinck

SOURCE Skyhawk Therapeutics

These press releases may also interest you

at 22:31
CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) updated results from the CS1001-201 trial in a poster presentation at the 2019 American Society of Hematology (ASH) Annual Meeting. CS1001-201 trial is a single-arm, multicenter Phase II...

at 21:07
Following the release of details from a surprise billing agreement between Senate Health, Education, Labor and Pensions (HELP) Committee Chairman Lamar Alexander (R-TN) and House Energy and Commerce Committee Chairman Frank Pallone Jr. (D-NJ) and...

at 21:05
Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the pricing of its underwritten public offering of 11,115,165...

at 20:00
A team led by Stavros Zanos, MD, PhD, assistant professor at the Feinstein Institutes for Medical Research, has published an overview of how bioelectronic medicine may be used to treat pulmonary arterial hypertension (PAH) in the Springer Nature...

at 19:50
North Bud Farms Inc. ("NORTHBUD" or the "Company") is pleased to announce the appointments of Mr. Ryan Brown as Executive Chairman of the Board of Directors, Mrs. Jennifer Ross-Carriere to the Board of Directors and Mr. Sean Homuth as Chief...

at 19:45
UCB, a global biopharmaceutical company, today announced positive results from a Phase II study (TP0001; NCT02718716) of its novel, first-in-class subcutaneous (SC, under the skin) monoclonal antibody, rozanolixizumab, in patients with primary immune...

News published on 12 november 2019 at 09:00 and distributed by: